Immunitybio Inc's shares surged after a significant meeting that hints at expansion prospects.
Immunitybio Inc. (NASDAQ:IBRX) is rising today, with shares climbing by 4.15% to close at $9.20. This increase follows a high-profile meeting between the company's founder, Dr. Patrick Soon-Shiong, and Turkish President Recep Tayyip Erdogan, sparking optimism about the company's expansion into Turkey.
Investor takeaway: Investors are showing confidence in Immunitybio's growth potential, especially with plans to expand its FDA-approved immunotherapy drug, Anktiva, into new markets.
Advertisement
Immunitybio Inc
IBRX.US
IBRX.US
Immunitybio Inc
WealthAwesomeMarket cap
$9.03B
52W high
$12.43
52W low
$1.95
1W change
-4.95%
Beta
0.14
Analyst Price Targets
Based on 5 analysts covering IBRX · as of Sep 17, 2026
Wall Street analysts forecast IBRX stock price to rise 44.4% over the next 12 months.
Consensus
Strong Buy4.60 / 5.00
Avg. Target
C$12.75
+44.4% Upside
Current Price
C$8.83
Last close
Analyst Breakdown (5 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on IBRX's historical volatility
30-Day Vol
62.0%
Annualized
90-Day Vol
63.6%
Annualized
Trend (90d)
-3.8%
Annualized drift
90d Mean
C$8.71
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$8.79 | C$7.10 – C$10.89 |
| 60 trading days | C$8.75 | C$6.47 – C$11.84 |
| 90 trading days | C$8.71 | C$6.01 – C$12.62 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Immunitybio Inc. shares rise by 4.15%
The stock's rise is fueled by optimism surrounding its expansion plans and recent financial performance.
Bull case
The meeting with President Erdogan indicates strong governmental support for Immunitybio's expansion plans, which could lead to increased revenue from new markets. The company's recent fundraising efforts and impressive revenue growth in Q2 further strengthen its financial position.
Bear case
Despite the positive momentum, Immunitybio faces challenges, including a widening net loss and high operational costs. Investors should remain cautious as the company navigates its growth strategy amidst these financial hurdles.
Significant Meeting Sparks Investor Optimism
Advertisement
The meeting between Dr. Patrick Soon-Shiong and President Erdogan has ignited investor enthusiasm, suggesting that Immunitybio's plans for expansion into Turkey are gaining traction. The Turkish government shared a photo of the two leaders, which Soon-Shiong reposted, highlighting Turkey's potential as a regional center for cancer treatment.
Strong Financial Performance Underpins Growth
Immunitybio's recent financial results have been encouraging, with Q2 revenues nearly doubling to $51.24 million compared to the previous year. This growth, driven by the FDA-approved drug Anktiva, positions the company favorably as it seeks to expand its market presence.
Institutional Support Remains Strong
The growing interest from institutional investors further strengthens the case for Immunitybio. Data shows a rise in hedge fund investments, with a significant increase in their combined holdings, suggesting confidence in the company's future prospects.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
